TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
|Slideshows|November 8, 2013
Psych Tweets of the Week–November 8, 2013
Noteworthy tweets in the world of mental health, week ending November 8, 2013, from NIMH, PsychCentral, Nature News, Time to Change, LA Times Health, and Neuro Skeptic.
Advertisement
Noteworthy tweets in the world of mental health, week ending November 8, 2013, from NIMH, PsychCentral, Nature News, Time to Change, LA Times Health, and Neuro Skeptic. A big thanks to all of our followers on @PsychTimes.
Advertisement
Related to this article
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
APSARD is preparing US adult ADHD guidelines, delivering long-awaited screening, diagnosis, and treatment recommendations as experts discuss the upcoming release.
Review top pipeline updates from last week.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
3
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5